Absence of histologic retinal toxicity of intravitreal bevacizumab in a rabbit model

被引:106
作者
Bakri, Sophie J.
Cameron, J. Douglas
McCannel, Colin A.
Pulido, Jose S.
Marler, Ronald J.
机构
[1] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Scottsdale, AZ USA
关键词
D O I
10.1016/j.ajo.2006.03.058
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE: To evaluate the retinal toxicity of intravitreal bevacizumab in an animal model. DESIGN: Animal study. METHODS: Bevacizumab was injected into the vitreous of one eye of each of eight Dutch-belted rabbits; the other eye served as a control. Four rabbits received a dose of 1.25 mg/0.05 ml of bevacizumab intravitreally into one eye, and the other four rabbits were injected with 2.5 mg/0.1 ml of bevacizumab intravitreally into one eye. At one month, the rabbits were killed and both eyes enucleated. The eyes were fixed with paraformaldehyde 2% and examined by light microscopy. RESULTS: In all injected and control eyes, there was mild vacuolization in the ganglion cell layer, and disruption of photoreceptor outer segments in both treated and control eyes, to the same degree, consistent with autolysis. The optic nerve, retina, and retinal pigment epithelium were otherwise normal by light microscopy with no evidence of toxicity. CONCLUSIONS: Intravitreal bevacizumab at doses of 1.25 mg and 2.5 mg showed no signs of retinal or optic nerve toxicity by light microscopy in this rabbit model.
引用
收藏
页码:162 / 164
页数:3
相关论文
共 8 条
[1]   Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration [J].
Avery, RL ;
Pieramici, DJ ;
Rabena, MD ;
Castellarin, AA ;
Nasir, MA ;
Giust, MJ .
OPHTHALMOLOGY, 2006, 113 (03) :363-372
[2]  
BAKRI SJ, 2006, EYE 0505
[3]   Testing intravitireal toxicity of bevacizumab (Avastin) [J].
Manzano, Roberta P. A. ;
Peyman, Gholam A. ;
Khan, Palwasha ;
Kivilcim, Muhamet .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03) :257-261
[4]   Intravitreal bevacizumab (avastin) for refractory pseudophakic cystoid macular edema [J].
Mason, John O., III ;
Albert, Michael A., Jr. ;
Vail, Rachel .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03) :356-357
[5]   Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for macular edema from central retinal vein occlusion [J].
Rosenfeld, PJ ;
Fung, AE ;
Puliafito, CA .
OPHTHALMIC SURGERY LASERS & IMAGING, 2005, 36 (04) :336-339
[6]   Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin®) for neovascular age-related macular degeneration [J].
Rosenfeld, PJ ;
Moshfeghi, AA ;
Puliafito, CA .
OPHTHALMIC SURGERY LASERS & IMAGING, 2005, 36 (04) :331-335
[7]   Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin) [J].
Shahar, Jonathan ;
Avery, Robert L. ;
Heilweil, Gad ;
Barak, Adiel ;
Zemel, Esther ;
Lewis, Geoffrey P. ;
Johnson, Patrick T. ;
Fisher, Steven K. ;
Perlman, Ido ;
Loewenstein, Anat .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03) :262-269
[8]   Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage [J].
Spaide, Richard F. ;
Fisher, Yale L. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (03) :275-278